Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Chemotherapy of leishmaniasis: present challenges

2017; Cambridge University Press; Volume: 145; Issue: 4 Linguagem: Inglês

10.1017/s0031182016002523

1469-8161

Sílvia Reni Bortolin Uliana, Cristiana T. Trinconi, Adriano C. Coelho,

Synthesis and Biological Evaluation

SUMMARY Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases of our time, affecting millions of people worldwide. The treatment of these serious diseases rely on a few chemotherapeutic agents, most of which are of parenteral use and induce severe side-effects. Furthermore, rates of treatment failure are high and have been linked to drug resistance in some areas. Here, we reviewed data on current chemotherapy practice in leishmaniasis. Drug resistance and mechanisms of resistance are described as well as the prospects for applying drug combinations for leishmaniasis chemotherapy. It is clear that efforts for discovering new drugs applicable to leishmaniasis chemotherapy are essential. The main aspects on the various steps of drug discovery in the field are discussed.